Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC.

被引：27

作者：

Antonia, Scott Joseph

Goldberg, Sarah B.

Balmanoukian, Ani Sarkis

Sanborn, Rachel E.

Steele, Keith

Narwal, Rajesh

Robbins, Paul B.

Gu, Yu

Karakunnel, Joyson Joseph

Rizvi, Naiyer A.

机构：

[1] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA

[2] Yale Canc Ctr, New Haven, CT USA

[3] Angeles Clin & Res Inst, Los Angeles, CA USA

[4] Providence Canc Ctr, Earle A Chiles Res Inst, Portland, OR USA

[5] MedImmune, Gaithersburg, MD USA

[6] Columbia Univ, Med Ctr, New York, NY USA

来源：

关键词：

D O I：

10.1200/jco.2015.33.15_suppl.3014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3014

引用

页数：1